FINANCING EXPENSIVE ANTICANCER DRUGS IN HOSPITALS- TOWARDS TRANSPARENCY TO IMPROVE PATIENT ACCESS

Author(s)

Silva ML, Aulois-Griot M
University of Bordeaux, Bordeaux, France

OBJECTIVES

: Innovative cancer therapies are funded in French hospitals via the “liste-en-sus”, meaning “in addition” to the Diagnosis-Related Group-Based (DRG) financing system. The Health Ministry monthly publishes an updated list, where anticancer drugs are predominantly expensive. Given this budgetary impact and the evolution of the legal framework of the list, this study assesses the criteria for inclusion/exclusion of anticancer drugs from the liste-en-sus

METHODS

: Anticancer drugs were extracted by ATC code from the publicly available liste-en-sus

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PCN213

Topic

Epidemiology & Public Health, Health Policy & Regulatory

Topic Subcategory

Disease Classification & Coding, Reimbursement & Access Policy

Disease

Oncology

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×